Safety/Efficacy Findings Support Cabozantinib in RAI-Refractory DTC
February 1st 2024Francis P. Worden, MD, reviews the progression-free survival data and safety findings from the phase 3 COSMIC-311 study which evaluated treatment with cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer.